Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
Year: 2020
Type: article
Abstract: Evolving treatments, disease phenotypes, and biology, together with a changing drug development environment, have created the need to revise castration-resistant prostate cancer (CRPC) clinical trial recommendations to succeed those from prior Prostate Cancer Clinical Trials Working Groups.
DOI: 10.17615/0sts-cx31
Authors: Armstrong, Andrew J., Morris, Michael J., Stadler, Walter M., Kelly, Wm. Kevin, Fizazi, Karim, Antonarakis, Emmanuel S., Schwartz, Lawrence H., Small, Eric J., Scher, Howard I., Slovin, Susan F., Sternberg, Cora N., Basch, Ethan, Chi, Kim N., Hussain, Maha, Carducci, Michael A., Ryan, Charles J., Sartor, Oliver, Heath, Elisabeth I., Stein, Mark N., Corn, Paul G., Wilding, George, Halabi, Susan, Nelson, Peter S., Logothetis, Christopher, Dreicer, Robert, Rathkopf, Dana E., Smith, Matthew Raymond, Liu, Glenn, Kantoff, Philip W., Nanus, David, Beer, Tomasz M., Higano, Celestia, George, Daniel J., De Bono, Johann S., Taplin, Mary-Ellen
Institution: University of North Carolina at Chapel Hill
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W4298853945